Laurus Labs Limited — Capital/Financing Update 2019

Sep 18, 2019

==> picture [54 x 67] intentionally omitted <==

ToThe Corporate Relations DepartmentBSE LimitedPhiroz Jeejeebhoy Towers,25thFloor,Dalal StreetMumbai - 400001Code: 540222	ToThe Listing DepartmentNational Stock ExchangeofIndia LimitedExchange Plaza,Bandra Kurla Complex, Bandra (East)Mumbai-400051Code:LAURUSLABS

PRESS RELEASE

==> picture [113 x 37] intentionally omitted <==

LAURUS LABS TO ACQUIRE THE SUBSIDIARY COMPANY OF ASPEN PHARMACARE, SOUTH AFRICA

Hyderabad, September 18, 2019, Laurus Labs Ltd. (BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01010)

Laurus Labs Limited, a leading research and development driven pharmaceutical company (“Company”), has agreed to acquire 100% shares of Phekolong Pharmaceuticals Pty Ltd, a wholly owned subsidiary company of Pharmacare Ltd. t/a Aspen Pharmacare, South Africa, subject to completion of conditions precedent, by way of cash consideration of ZAR 75,000 (Seventy-five thousand South African Rands). The acquisition is expected to be completed by end of November, 2019.

At the conclusion of the transaction, all residual assets and liabilities that are within the target company immediately prior to completion will be for Pharmacare Limited’s account and accordingly all such assets and liabilities will be transferred from the target company to Pharmacare Limited immediately prior to completion.

This transaction will provide to the Company access to the South African public antiretroviral (“ARV”) sector, which manages the world’s largest public ARV programme. While Aspen will continue to manufacture the finished dose form ARV’s for the South African public sector, the distribution to this sector will be through the Company’s newly acquired South African subsidiary.

About Laurus Labs Limited:

Laurus Labs is a leading research & development driven and fully integrated pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. The company has also ventured into develop a Finished Dosages Forms on the back of existing strengths in APIs with a current capacity of 5 billion units per year, expandable up to 8 billion units per year. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses. Corporate Identification No: L24239AP2005PLC047518.

For more information about us, please visit http://www.lauruslabs.com or Contact particulars:

Pavan Kumar N

Laurus Labs Ltd.

Tel: +91 40 3980 4380 Email: mediarelations@lauruslabs.com

==> picture [62 x 64] intentionally omitted <==

==> picture [81 x 68] intentionally omitted <==

DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

SEPTEMBER 18, 2019

Press Release